Christophe Schmitt

ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 8

Top Venues

Diabetes, obesity & metabolism

Clinical pharmacokinetics

Journal of clinical pharmacology

Research and practice in thrombosis and haemostasis

F. Hoffmann La Roche

This page only lists publications with an associated author ORCID identifier.

Affiliation History

F. Hoffmann La Roche

Switzerland

Clinical Pharmacologist :: Department of Clinical Pharmacology

Publications

Renchi Yang, Shujie Wang, Xuefeng Wang, Jing Sun, Ampaiwan Chuansumrit, Jianfeng Zhou, Christophe Schmitt, Wanling Hsu, Jeffrey Xu, Lindong Li, Tiffany Chang, Xielan Zhao
Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5). Research and practice in thrombosis and haemostasis 6 (2) (2022)
Christophe Schmitt, Laura Brockwell, Mylène Giraudon, Mauro Zucchetto, Lisa Christ, Bettina Bannert, Thomas Daikeler, Peter M Villiger
Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study. Arthritis research & therapy 24 (1) (2022)
Koichiro Yoneyama, Christophe Schmitt, Tiffany Chang, Christophe Dhalluin, Sayaka Nagami, Claire Petry, Gallia G Levy
A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A. Journal of clinical pharmacology (2021)
Fredrik Jonsson, Christophe Schmitt, Claire Petry, Francois Mercier, Nicolas Frey, Sylvie Retout
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. Clinical pharmacokinetics 60 (7) (2021)
Christophe Schmitt, Thomas Emrich, Sammy Chebon, Elena Fernandez, Claire Petry, Koichiro Yoneyama, Anna Kiialainen, Monet Howard, Markus Niggli, Ido Paz-Priel, Tiffany Chang
Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia : the official journal of the World Federation of Hemophilia 27 (6) (2021)
Koichiro Yoneyama, Christophe Schmitt, Naoki Kotani, Gallia G Levy, Ryu Kasai, Satofumi Iida, Midori Shima, Takehiko Kawanishi
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clinical pharmacokinetics 57 (9) (2019)
Agnès Portron, Shirin Jadidi, Neena Sarkar, Richard DiMarchi, Christophe Schmitt
Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. Diabetes, obesity & metabolism 19 (10) (2017)
Christophe Schmitt, Agnès Portron, Shirin Jadidi, Neena Sarkar, Richard DiMarchi
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes, obesity & metabolism 19 (10) (2017)

Christophe Schmitt.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Christophe Schmitt